Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Am J Hematol. 2022 Oct 31;98(1):79–89. doi: 10.1002/ajh.26757

Figure 2: Cytogenetic and genetic predictors of MRD− response pre allo-SCT.

Figure 2:

Univariate analyses of pre-treatment genetic predictors of achieving MRD− CR/CRi/MLFS prior to allo-SCT. Each column and row denote an individual patient and gene/cytogenetic abnormality, respectively. MRD response are shown in the top rows. Genes and cytogenetic abnormalities are each are ordered by odds ratio (OR) of achieving an MRD− CR/CRi/MLFS from lowest to highest. Patients who had at least one mutation in the 19 most commonly mutated genes covered in all sequencing platforms are displayed.